var data={"title":"Anthrax vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Anthrax vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5648?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=anthrax-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Anthrax vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135675\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BioThrax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135690\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135677\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Preexposure prophylaxis:</b> Adults &le;65 years:</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">IM (preferred):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Primary immunization: Three injections of 0.5 mL each given at day 0, 1 month, and 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Booster injections: 0.5 mL each should be given 6 and 12 months after completion of the primary series and at 1-year intervals thereafter for persons who remain at risk</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Primary immunization: Four injections of 0.5 mL each given at day 0, 2 weeks, 4 weeks, and 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Booster injections: 0.5 mL each should be given 6 and 12 months after completion of the primary series and at 1-year intervals thereafter for persons who remain at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <b>Note:</b> SubQ administration is only to be used for primary immunization in persons who are at risk for hematoma formation following IM injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Postexposure prophylaxis (inhalation exposure):</b> SubQ: Three injections of 0.5 mL each given at day 0, 2 weeks, and 4 weeks post-exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ACIP recommendations (CDC [Wright 2010]): Administer with a 60-day course of antibiotics. (Vaccination should begin within 10 days of exposure. Refer to guidelines provided as part of emergency use authorization [EUA] or investigational new drug [IND] application at the time of the event).  <b>Note:</b> Additional considerations for postexposure prophylaxis following occupational exposures:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Fully vaccinated:</i> Personnel who have completed the primary vaccination series and booster injections do not require postexposure prophylaxis if wearing protective equipment. If respiratory protection is disrupted, a 30-day course of antimicrobial therapy is recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Previously unvaccinated:</i> Workers should receive the vaccine as directed per postexposure prophylaxis along with the 60-day course of antimicrobial therapy (antimicrobial therapy should continue for 14 days after the third dose of PEP vaccine), then switch to the licensed regimen at the 6-month dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Partially vaccinated:</i> Any person who started but did not complete the primary vaccination series should receive a 30-day course of antimicrobial  therapy and continue with the primary vaccination schedule.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135684\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Children &lt;18 years: Safety and efficacy have not been established. <b>Note:</b> Use in children is recommended by the ACIP as determined on an event-by-event basis; refer to adult dosing for postexposure prophylaxis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135678\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Safety and efficacy have not been established in persons &gt;65 years of age. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135661\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BioThrax: <i>Bacillus anthracis</i> proteins (5 mL) [contains aluminum, natural rubber/natural latex in packaging]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135647\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11216961\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">For ordering information contact the manufacturer at 866-300-7602 or http://biothrax.com/forhealthpros/clinicalInfo/ordering.aspx. A supply is also maintained in the Strategic National Stockpile for post-exposure prophylaxis in the event of a terrorist attack with anthrax. Additional information from the CDC is available at https://www.cdc.gov/laboratory/drugservice/formulary.html.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734185\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the CDC-approved Vaccine Information Statement (VIS) is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/anthrax.html&amp;token=nGTrk6nnonhuku0Yq+nxpjgFRzAfvIqfPSpxsngjzE9qrevRFQcYAN6ez0qyP9i+Emyll9jaCJMfGV7PoQ8ddq8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=8625\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/anthrax.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135663\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Shake well before use. Do not use if discolored or contains particulate matter. Do not use the same site for more than one injection. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Preexposure (routine vaccination): For IM administration into the deltoid muscle; do not inject IV or intradermally. For patients at risk of bleeding/hematoma following IM injection, the vaccine can be administered SubQ over the deltoid muscle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postexposure prophylaxis: Administer SubQ over the deltoid muscle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135662\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax prevention:</b> Active immunization against <i>Bacillus anthracis</i> in persons 18 to 65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pre-exposure: For pre-exposure prophylaxis of disease in persons whose occupation or other activities place them at high risk of exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Post-exposure: For post-exposure prophylaxis of disease following suspected or confirmed <i>Bacillus anthracis</i> exposure, when administered in conjunction with recommended antibacterial drugs.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination (pre-exposure vaccination) for the following (CDC [Wright 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons who work directly with the organism in the laboratory</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons who handle animals or animal products only when</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- potentially infected in research settings;</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- in areas of high incidence of enzootic anthrax; or</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- where standards and restrictions are not sufficient to prevent exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Military personnel deployed to areas with high risk of exposure as recommended by the Department of Defense (DoD)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons engaged in environmental investigations or remediation efforts</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Routine immunization for the general population is not recommended. Routine vaccination may be offered to emergency and other responders (police and fire departments, the National Guard, etc.) on a voluntary basis under the direction of a comprehensive occupational health and safety program (CDC [Wright 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The ACIP recommends postexposure prophylaxis after inhalation exposure to aerosolized <i>Bacillus anthracis</i> spores for the following (in the absence of completing a preexposure, routine vaccination schedule) (CDC [Wright 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The general public, including pregnant and breast-feeding women</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Medical professionals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Children ages 0 to 18 years as determined on an event-by-event basis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons engaged in handling certain animals or animal products</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons who work directly with the organism in the laboratory (postexposure vaccination dependent upon pre-event vaccination status)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Military personnel as recommended by the DoD</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons engaged in environmental investigations or remediation efforts (postexposure vaccination dependent upon pre-event vaccination status)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Emergency and other responders (police and fire departments, the National Guard, etc.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Persons working in postal facilities</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135653\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Burning sensation (45% to 97%), fatigue (6% to 13%), headache (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Edema at insertion site (subcutaneous: 17% to 46%; intramuscular: 5% to 30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Tenderness at injection site (subcutaneous: 48% to 72%; intramuscular: 41% to 51%), erythema at injection site (subcutaneous: 53% to 71%; intramuscular: 15% to 48%), warm sensation at injection site (subcutaneous: 29% to 51%; intramuscular: 4% to 19%), injection site nodule (subcutaneous: 21% to 42%; intramuscular: 3% to 9%), induration at injection site (subcutaneous: 26% to 40%; intramuscular: 7% to 23%), itching at injection site (subcutaneous: 3% to 26%; intramuscular: 1% to 10%), pain at injection site (12% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Decreased range of motion (5% to 15%; arm), myalgia (3% to 13%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Lymphadenopathy (&le;2%; painful axillary nodes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Bruising at injection site (2% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Alopecia, anaphylactoid reaction, anaphylaxis, angioedema, arthralgia, arthropathy, cellulitis, dizziness, erythema multiforme, flu-like symptoms, flushing, hypersensitivity reaction, insomnia, lymphadenopathy, malaise, nausea, pain, paresthesia, pruritus, rhabdomyolysis, skin rash, Stevens-Johnson syndrome, syncope, tremor, ulnar nerve neuropathy, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135666\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Anaphylactic or anaphylactic-like reaction following a previous dose of anthrax vaccine or any component of the formulation including aluminum, benzethonium chloride, and formaldehyde.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135650\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever) in preexposure vaccination programs; may administer to patients with mild acute illness (with or without fever). When used for postexposure prophylaxis, consider the benefits versus risks in patients with moderate or severe acute illness (CDC [Wright 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anthrax disease: Persons with a history of anthrax disease may have an increased risk for severe local adverse reactions from the vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]). For patients at risk of hemorrhage following IM injection, the vaccine can be administered SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous or gastrointestinal anthrax exposure: Vaccination is not recommended after cutaneous or gastrointestinal exposures that pose no risk of inhalational exposure to <i>Bacillus anthracis</i> spores; antimicrobial postexposure prophylaxis may be considered in these patients (CDC [Wright 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]). For patients at risk of hemorrhage following IM injection, the vaccine can be administered SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Safety and efficacy have not been established in adults &ge;65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298756\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135654\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8625&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135669\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal developmental toxicity studies. Data from the Department of Defense suggest the vaccine may be linked with a slightly increased number of atrial septal defects when given during the first trimester of pregnancy; however, when premature infants are excluded from analysis, the association is not statistically significant. Current ACIP guidelines recommend deferring preexposure vaccination when possible; however, postexposure prophylaxis is recommended in pregnant women. Male fertility is not affected by vaccine administration (CDC [Wright 2010]).  Health care providers are encouraged to enroll pregnant women exposed to this vaccine in Emergent&rsquo;s vaccination pregnancy registry (1-619-553-9255).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135670\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is excreted into breast milk; however, the administration of nonlive vaccines during breastfeeding is generally not medically contraindicated. Current ACIP guidelines recommend deferring preexposure vaccination when possible; however, postexposure prophylaxis is recommended in breastfeeding women (CDC [Wright 2010]). The manufacturer recommends that caution be used if administered to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135658\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for local reactions, chills, fever, anaphylaxis. Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F135649\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Active immunization against <i>Bacillus anthracis</i>. The vaccine is prepared from a cell-free filtrate of <i>B. anthracis</i>, but no dead or live bacteria. Completion of the entire vaccination series is required for full protection; annual boosters are required to maintain immunity. </p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    BioThrax (anthrax vaccine adsorbed) [prescribing information]. Lansing, MI: Emergent BioDefense Operations Lansing; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anthrax-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. <i>MMWR Recomm Rep</i>. 2010;59(RR-6):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/anthrax-vaccine-drug-information/abstract-text/20651644/pubmed\" target=\"_blank\" id=\"20651644\">20651644</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8625 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F135675\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F135690\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F135677\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F135684\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F135678\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F135661\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F135647\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11216961\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734185\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F135663\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F135662\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F135653\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F135666\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F135650\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298756\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F135654\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F135669\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F135670\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F135658\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F135649\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8625|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=anthrax-vaccine-patient-drug-information\" class=\"drug drug_patient\">Anthrax vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}